Cargando…

Correction: CircPTPRA blocks the recognition of RNA N(6)-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression

Detalles Bibliográficos
Autores principales:	Xie, Fei, Huang, Chao, Liu, Feng, Zhang, Hui, Xiao, Xingyuan, Sun, Jiayin, Zhang, Xiaoping, Jiang, Guosong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624052/ https://www.ncbi.nlm.nih.gov/pubmed/36316700 http://dx.doi.org/10.1186/s12943-022-01677-8

Ejemplares similares

CircPTPRA blocks the recognition of RNA N(6)-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression
por: Xie, Fei, et al.
Publicado: (2021)

CircPTPRA acts as a tumor suppressor in bladder cancer by sponging miR-636 and upregulating KLF9
por: He, Qingqing, et al.
Publicado: (2019)

The circRNA circPTPRA suppresses epithelial-mesenchymal transitioning and metastasis of NSCLC cells by sponging miR-96-5p
por: Wei, Siliang, et al.
Publicado: (2019)

CircPTPRA promotes the progression of pancreatic ductal adenocarcinoma via the miR‐140‐5p/LMNB1 axis
por: Fu, Wen, et al.
Publicado: (2023)

Recognition of RNA N(6)-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation
por: Huang, Huilin, et al.
Publicado: (2018)

IGF2BP3 is an essential N(6)-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells
por: Xu, Xin, et al.
Publicado: (2022)

CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer
por: Zhang, Hui, et al.
Publicado: (2021)

PTPRA facilitates cancer growth and migration via the TNF-α-mediated PTPRA-NF-κB pathway in MCF-7 breast cancer cells
por: Lin, Canfeng, et al.
Publicado: (2020)

IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader
por: Hu, Xiaoge, et al.
Publicado: (2019)

circNR3C1 Suppresses Bladder Cancer Progression through Acting as an Endogenous Blocker of BRD4/C-myc Complex
por: Xie, Fei, et al.
Publicado: (2020)

IGF2BP2 Regulates MALAT1 by Serving as an N6-Methyladenosine Reader to Promote NSCLC Proliferation
por: Han, Le, et al.
Publicado: (2022)

RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation
por: Zhu, Kai, et al.
Publicado: (2023)

circRNA_PTPRA functions as a sponge of miR-582-3p to regulate hepatocellular carcinoma cell proliferation, migration, invasion and apoptosis
por: Jin, Yanlin, et al.
Publicado: (2021)

Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
por: Chen, Pin, et al.
Publicado: (2023)

RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer
por: Yang, Zhou, et al.
Publicado: (2020)

N(6)-methyladenosine reader IGF2BP3 as a prognostic Biomarker contribute to malignant progression of glioma
por: Zheng, Xin, et al.
Publicado: (2023)

Silencing of circCRIM1 Drives IGF2BP1-Mediated NSCLC Immune Evasion
por: Peng, Wenbei, et al.
Publicado: (2023)

N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis
por: Peng, Wan-Xin, et al.
Publicado: (2022)

Circular RNA circIGF2BP3 Promotes the Proliferation and Differentiation of Chicken Primary Myoblasts
por: Wang, Xiaotong, et al.
Publicado: (2023)

CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis
por: Zhang, Wei, et al.
Publicado: (2021)

Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis
por: Wu, Tao, et al.
Publicado: (2022)

IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N(6)-methyladenosine-dependent binding
por: Zhang, Junzhe, et al.
Publicado: (2022)

MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma
por: Du, Mingyu, et al.
Publicado: (2022)

N(6)-methyladenosine (m(6)A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1
por: Zhang, Zili, et al.
Publicado: (2022)

circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA
por: Okholm, Trine Line Hauge, et al.
Publicado: (2023)

circRNA N6-methyladenosine methylation in preeclampsia and the potential role of N6-methyladenosine-modified circPAPPA2 in trophoblast invasion
por: Zhang, Yonggang, et al.
Publicado: (2021)

Resequencing and Association Analysis of PTPRA, a Possible Susceptibility Gene for Schizophrenia and Autism Spectrum Disorders
por: Xing, Jingrui, et al.
Publicado: (2014)

CircARID1A binds to IGF2BP3 in gastric cancer and promotes cancer proliferation by forming a circARID1A-IGF2BP3-SLC7A5 RNA–protein ternary complex
por: Ma, Qiang, et al.
Publicado: (2022)

Circular RNA circ-TNPO3 suppresses metastasis of GC by acting as a protein decoy for IGF2BP3 to regulate the expression of MYC and SNAIL
por: Yu, Ting, et al.
Publicado: (2021)

IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer
por: Huang, Wei, et al.
Publicado: (2023)

Investigation of Igf-1, Igf-Bp3 and Igf-Bp5 levels in umbilical cord blood of infants with developmental dysplasia of the hip
por: DEMİREL, Esra, et al.
Publicado: (2023)

Does a rare mutation in PTPRA contribute to the development of Parkinson’s disease in an Australian multi-incident family?
por: Hill, Melissa A., et al.
Publicado: (2022)

N(6)-methyladenosine-modified circIGF2BP3 inhibits CD8(+) T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer
por: Liu, Zhenchuan, et al.
Publicado: (2021)

N(6)-methyladenosine (m(6)A) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis
por: Yuan, Bao, et al.
Publicado: (2023)

RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA
por: Fan, Jin, et al.
Publicado: (2023)

A novel feedback regulated loop of circRRM2-IGF2BP1-MYC promotes breast cancer metastasis
por: Hao, Ran, et al.
Publicado: (2023)

RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner
por: Cai, Xianlei, et al.
Publicado: (2021)

HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway
por: Lv, Jiancheng, et al.
Publicado: (2023)

FLOT1, stabilized by WTAP/IGF2BP2 mediated N6-methyladenosine modification, predicts poor prognosis and promotes growth and invasion in gliomas
por: Song, Tao, et al.
Publicado: (2023)

Targeting IGF2BP3 in Cancer
por: Liu, Xin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f38c55spp0ubiq4dcc0fv68qhu